Search This Blog

Monday, June 8, 2026

Tango Therapeutics 92% ORR for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3

 

Tango Therapeutics reports 92% ORR for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, plans Phase 3 development

  • Initial Phase 1/2 trial data support advancing vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)